Editorial
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jan 7, 2008; 14(1): 1-14
Published online Jan 7, 2008. doi: 10.3748/wjg.14.1
Table 1 Agents for anti-EGFR-based therapy of solid tumours
NameTargetMechanism Current status
Small molecule inhibitors
Gefitinib (Iressa)EGFRReversibly acting tyrosine kinase inhibitorApproved for NSCLC with restricted indications
PhaseIfor HCC[133]
Erlotinib (Tarceva)EGFRReversibly acting tyrosine kinase inhibitorApproved for NSCLC and pancreatic cancer
Phase II for hepatocellular cancer[33]
EKB-569EGFRIrreversibly acting tyrosine kinase inhibitorPhase I/II for colorectal cancer[134]
Phase II for NSCLC[135]
Lapatinib (Tykerb)EGFR, erbB2Reversibly acting tyrosine kinase inhibitorPhase III for breast cancer
Phase II for HCC[136]
Canertinib (CI-1033)Pan-erbBIrreversibly acting tyrosine kinase inhibitorPhase II for SCC and ovarian cancer[137]
BMS-599626EGFR, erbB2Reversibly acting tyrosine kinase inhibitorPhase II for HCC [138]
Monoclonal antibodies
CetuximabEGFRApproved for colorectal cancer
Phase III for head and neck cancer, NSCLC and pancreatic cancer
Phase II for HCC[139]
TrastuzumaberbB2Approved for breast cancer
ABX-EGFEGFRPhase III for colorectal-, head and neck-, and renal cell cancer
Matuzumab (EMD 72 000)EGFRPhase I/II for NSCLC[140], ovarian-[141], pancreatic cancer[142]